| 重症新型冠状病毒肺炎对冠心病药物治疗的影响及策略 |
| |
| 引用本文： | 叶添宝,沈成兴. 重症新型冠状病毒肺炎对冠心病药物治疗的影响及策略[J]. 中国动脉硬化杂志, 2020, 28(5): 382-385 |
| |
| 作者姓名： | 叶添宝 沈成兴 |
| |
| 作者单位： | 上海交通大学附属第六人民医院心内科,上海市 200233 |
| |
| 基金项目： | 国家自然科学基金项目(81871105) |
| |
| 摘 要： | 新型冠状病毒肺炎患者不仅具有典型的呼吸道症状,同时也表现出一定程度的心脏损伤。合并心血管疾病的新型冠状病毒肺炎患者病情容易恶化,病死率高。冠心病作为中老年人最常见的心血管疾病广泛存在于重症新型冠状病毒肺炎患者中,对病程转归造成严重的影响。本文将探讨重症新型冠状病毒肺炎对冠心病患者药物治疗的影响,以优化治疗策略,改善患者的预后。
|
| 关 键 词： | 新型冠状病毒肺炎 冠心病 药物治疗 |
| 收稿时间： | 2020-03-07 |
| 修稿时间： | 2020-03-17 |
Pharmacotherapeutic effects and strategies of coronary heart disease in patients with severe novel coronavirus pneumonia |
| |
| YE Tianbao,SHEN Chengxing. Pharmacotherapeutic effects and strategies of coronary heart disease in patients with severe novel coronavirus pneumonia[J]. Chinese Journal of Arteriosclerosis, 2020, 28(5): 382-385 |
| |
| Authors: | YE Tianbao SHEN Chengxing |
| |
| Affiliation: | Department of Cardiology, Shanghai Sixth People''s Hospital, Shanghai Jiaotong University, Shanghai 200233, China |
| |
| Abstract: | Patients with corona virus disease 2019 (COVID-19) presented typical respiratory symptoms, as well as a certain degree of cardiac injury. COVID-19 patients with cardiovascular diseases are prone to deterioration and high mortality. Coronary heart disease, as the most common cardiovascular disease in the middle-aged and the elderly, widely exists in severe COVID-19 patients, which has a serious impact on the course of disease. This article will discuss the influence of severe COVID-19 on the drug treatment of coronary heart disease, to optimize the treatment strategy and improve the prognosis of patients. |
| |
| Keywords: | corona virus disease 2019 coronary heart disease drug therapy |
| 本文献已被 CNKI 维普 等数据库收录！ |
| 点击此处可从《中国动脉硬化杂志》浏览原始摘要信息 |
|
点击此处可从《中国动脉硬化杂志》下载全文 |
|
